These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15836574)

  • 1. Neuroleptics in headache.
    Siow HC; Young WB; Silberstein SD
    Headache; 2005 Apr; 45(4):358-71. PubMed ID: 15836574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' preference for migraine preventive therapy.
    Peres MF; Silberstein S; Moreira F; Corchs F; Vieira DS; Abraham N; Gebeline-Myers C
    Headache; 2007 Apr; 47(4):540-5. PubMed ID: 17445103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. If 'atypical' neuroleptics did not exist, it wouldn't be necessary to invent them: perverse incentives in drug development, research, marketing and clinical practice.
    Charlton BG
    Med Hypotheses; 2005; 65(6):1005-9. PubMed ID: 16182461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sumatriptan and naproxen sodium for the acute treatment of migraine.
    Smith TR; Sunshine A; Stark SR; Littlefield DE; Spruill SE; Alexander WJ
    Headache; 2005 Sep; 45(8):983-91. PubMed ID: 16109111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype-driven preventive strategies for migraine and other headaches.
    Wheeler SD
    Neurologist; 2009 Mar; 15(2):59-70. PubMed ID: 19276783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Atypical antipsychotic-induced weight gain].
    Godlewska BR; Olajossy-Hilkesberger L; Marmurowska-Michałowska H; Olajossy M; Landowski J
    Psychiatr Pol; 2006; 40(5):995-1007. PubMed ID: 17217241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other.
    Fleischhacker WW; Widschwendter CG
    Curr Opin Psychiatry; 2006 Mar; 19(2):128-34. PubMed ID: 16612191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroergotamine: role in the treatment of migraine.
    Schürks M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
    Motlová L; Spaniel F; Höschl C; Balon R
    Ann Clin Psychiatry; 2007; 19(2):133-43. PubMed ID: 17612853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
    Chen LC; Ashcroft DM
    Headache; 2008 Feb; 48(2):236-47. PubMed ID: 18179569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of placebo in headache research.
    Diener HC; Schorn CF; Bingel U; Dodick DW
    Cephalalgia; 2008 Oct; 28(10):1003-11. PubMed ID: 18727647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.
    Dahlöf CG; Pascual J; Dodick DW; Dowson AJ
    Cephalalgia; 2006 Apr; 26(4):400-8. PubMed ID: 16556240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine.
    Sandrini G; Dahlöf CG; Mathew N; Nappi G
    Int J Clin Pract; 2005 Nov; 59(11):1356-65. PubMed ID: 16236092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial.
    Donaldson D; Sundermann R; Jackson R; Bastani A
    Am J Emerg Med; 2008 Feb; 26(2):124-30. PubMed ID: 18272089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of clinical trials using early acute intervention with oral triptans for migraine management.
    Dowson AJ; Mathew NT; Pascual J
    Int J Clin Pract; 2006 Jun; 60(6):698-706. PubMed ID: 16805756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive migraine treatment.
    Silberstein SD
    Neurol Clin; 2009 May; 27(2):429-43. PubMed ID: 19289224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.